title: Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients.
abstract: Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.
authors.affiliation: Division of Dermatology; Lung Infection and Immunity Unit.
authors.forename: Rannakoe J
authors.initials: RJ
authors.lastname: Lehloenya
authors.affiliation: Division of Infectious Disease and HIV Medicine, Department of Medicine.
authors.forename: Sipho
authors.initials: S
authors.lastname: Dlamini
authors.affiliation: Department of Paediatrics and Child Health , University of Cape Town , South Africa.
authors.forename: Rudzani
authors.initials: R
authors.lastname: Muloiwa
authors.affiliation: Division of Dermatology.
authors.forename: Betty
authors.initials: B
authors.lastname: Kakande
authors.affiliation: Division of Dermatology.
authors.forename: Mzudumile R
authors.initials: MR
authors.lastname: Ngwanya
authors.affiliation: Division of Dermatology.
authors.forename: Gail
authors.initials: G
authors.lastname: Todd
authors.affiliation: Lung Infection and Immunity Unit.
authors.forename: Keertan
authors.initials: K
authors.lastname: Dheda
keywords: alternative; rifabutin; rifampicin-associated drug eruption; tuberculosis HIV coinfection